FY2025 Earnings Forecast for Sanofi Issued By Zacks Research

Sanofi (NASDAQ:SNY) – Stock analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for Sanofi in a research report issued on Monday, November 10th. Zacks Research analyst Team now expects that the company will post earnings of $4.39 per share for the year, up from their previous estimate of $4.34. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q4 2025 earnings at $0.84 EPS, Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.49 EPS, Q4 2026 earnings at $1.23 EPS and FY2026 earnings at $4.90 EPS.

Several other brokerages have also issued reports on SNY. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, November 5th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Sanofi has an average rating of “Buy” and an average price target of $62.67.

Sanofi Stock Performance

NASDAQ SNY opened at $50.66 on Tuesday. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The company has a fifty day moving average of $48.66 and a 200-day moving average of $49.44. The company has a market capitalization of $124.40 billion, a P/E ratio of 11.86, a P/E/G ratio of 1.38 and a beta of 0.49. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.94 and a current ratio of 1.06.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 24th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.10. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business had revenue of $14.53 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same period last year, the firm posted $2.25 earnings per share. Sanofi’s quarterly revenue was down 7.5% on a year-over-year basis.

Hedge Funds Weigh In On Sanofi

A number of hedge funds have recently made changes to their positions in the business. Financial Consulate Inc. purchased a new stake in Sanofi during the 3rd quarter valued at approximately $26,000. Ameritas Advisory Services LLC bought a new stake in Sanofi in the 2nd quarter valued at $28,000. Accent Capital Management LLC bought a new stake in Sanofi in the 1st quarter valued at $29,000. Eastern Bank boosted its holdings in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares during the last quarter. Finally, Banque Transatlantique SA purchased a new position in shares of Sanofi during the first quarter valued at about $33,000. Institutional investors own 14.03% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.